GINWA(SH:600080)2024-12-25 11:02Financial Performance - The company's operating revenue for Q3 2023 was ¥147,435,488.04, representing a decrease of 10.34% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2023 was -¥6,257,459.32, a decline of 160.41% year-over-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,180,388.03, down 72.70% from the previous year[7]. - The basic earnings per share for Q3 2023 was -¥0.0168, a decrease of 160.42% compared to the same period last year[10]. - The weighted average return on equity was -0.38%, a decrease of 1.00 percentage points year-over-year[10]. - Net profit for the third quarter of 2023 was CNY -4,993,956.32, a significant decline compared to CNY 31,829,432.97 in the same quarter of 2022[35]. - The net profit attributable to the parent company's shareholders for the current period is -4,993,956.32, compared to a profit of 31,829,432.97 in the same period last year[38]. - The basic and diluted earnings per share for the current period are both -0.0134, down from 0.0853 in the previous year[38]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,050,925,875.34, an increase of 3.87% compared to the end of the previous year[10]. - Total assets as of the end of the reporting period were CNY 2,050,925,875.34, an increase from CNY 1,974,418,631.97 at the end of the previous year[32]. - Total liabilities increased to CNY 372,154,159.54 in 2023 from CNY 290,653,248.41 in 2022, marking a rise of 28.0%[32]. - The company’s total equity decreased slightly to CNY 1,678,771,715.80 from CNY 1,683,765,383.56, indicating a decline of 0.3%[32]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥11,949,314.66, a decrease of 28.52% compared to the same period last year[10]. - Cash inflow from operating activities for the first three quarters of 2023 is 441,830,298.33, slightly up from 441,329,151.28 in the same period last year[41]. - The net cash flow from operating activities is -11,949,314.66, compared to -9,297,386.75 in the previous year[41]. - Cash inflow from investment activities totals 1,446,976,524.92, compared to 983,848,470.29 in the same period last year[43]. - The net cash flow from investment activities is -48,514,725.24, down from a positive 64,166,189.36 in the previous year[43]. - Cash inflow from financing activities is 175,405,390.44, with a net cash flow of 67,366,210.20, compared to -176,530.76 in the previous year[43]. - The ending cash and cash equivalents balance is 439,540,865.47, up from 213,132,731.53 at the end of the previous year[43]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,854, with the top 10 shareholders holding a combined 56.4% of shares[17]. - The largest shareholder, Xing Boyue, holds 73,272,546 shares, representing 19.63% of total shares[17]. Research and Development - Research and development expenses increased by 37.95% year-to-date, reflecting higher investment in ongoing projects[14]. - Research and development expenses increased to CNY 8,860,272.09 in 2023 from CNY 6,422,923.40 in 2022, representing a growth of 38.0%[35]. - The company has signed a cooperation agreement to establish the "Western Jinhua Academician Workstation" with Academician Wang Songling's team, focusing on the development of a new drug for treating radiation-induced salivary gland damage[22]. - The new drug research project is still in the early stages, and its success is uncertain due to various influencing factors[22]. - The establishment of the workstation is not expected to have a significant short-term impact on the company's financial status or operating performance[22]. Other Financial Metrics - The company reported a significant decrease in government subsidies received, down 80.05% year-to-date[14]. - The company reported a decrease in sales expenses to CNY 240,889,890.91 from CNY 247,754,430.88, a reduction of 2.8%[35]. - The company's financial expenses showed a significant improvement, with a net financial income of CNY -1,573,662.54 compared to CNY -3,753,716.37 in the previous year[35]. - The company reported a significant reduction in other receivables, decreasing from ¥165,246,367.76 to ¥35,739,684.66, a decline of approximately 78.4%[27]. - The inventory increased to ¥28,438,540.88 from ¥25,150,619.56, reflecting an increase of about 9.1%[27]. - The company has not executed any mergers or acquisitions during the reporting period, with the merged entity reporting a net profit of 0[40].